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(Abstract) 
The increasing importance of immunoglobulins G (IgGs) as biotherapeutics calls 
for improved structural characterization methods designed for these large (~150 
kDa) macromolecules. Analysis workflows have to be rapid, robust, and require 
minimal sample preparation. In a previous work we showed the potential of 
Orbitrap Fourier transform mass spectrometry (FTMS) combined with electron 
transfer dissociation (ETD) for the top-down investigation of an intact IgG1, 
resulting in ~30% sequence coverage. Here, we describe a top-down analysis of 
two IgGs1 (adalimumab and trastuzumab) and one IgG2 (panitumumab) 
performed with ETD on a mass spectrometer equipped with a high-field Orbitrap 
mass analyzer. For the IgGs1, sequence coverage comparable to the previous 
results was achieved in a two-fold reduced number of summed transients, which 
corresponds, taken together with the significantly increased spectra acquisition 
rate, to ~six-fold improvement in analysis time. Furthermore, we studied the 
influence of ion-ion interaction times on ETD product ions for IgGs1, and the 
differences in fragmentation behavior between IgGs1 and IgG2, which present 
structural differences. Overall, these results reinforce the hypothesis that gas 
phase dissociation using both energy threshold-based and radical-driven ion 
activations is directed to specific regions of the polypeptide chains mostly by the 
location of disulfide bonds. 
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1. Introduction 
Monoclonal antibodies (mAbs) are an effective therapeutic tool in a variety of 
medical conditions such as cancer and inflammatory disease.[1] These large 
glycoproteins constitute the fastest growing class of biotherapeutics.[2, 3] The 
main class of antibodies employed as biopharmaceuticals is immunoglobulin G 
(IgG). IgGs are large (~150 kDa) biomolecules with a quaternary structure made 
of two ~25 kDa light and two ~50 kDa heavy chains, identical among themselves, 
with the latter being N-glycosylated, Supporting Information Figure S1. The four 
chains are interconnected and their tertiary/quaternary structure is reinforced 
by inter- and intra-molecular disulfide bridges. Heavy chains can be translated 
from different genes, and their sequence determines the so-called IgG isotype (or 
subclass). In the pharmaceutical industry, three of the four IgG isotypes are of 
interest: IgG1, IgG2, and IgG4. Although all isotypes share ~90% of homology in 
their amino acid sequences, the structure of their hinge regions and the disulfide 
bond connectivity differ significantly. IgG1 and IgG4 contain 16 disulfide bridges, 
two in the hinge region linking the heavy chains, one disulfide bridge linking 
each light chain to the corresponding heavy chain and 12 intramolecular bridges 
(2 and 4 for each light and heavy chain, respectively). IgG2 contains 18 disulfide 
bonds with four in the hinge region linking the two heavy chains together.[4, 5] 
Figure S1 compares the structures of an IgG1 and an IgG2. Note that the C-
terminal cysteine of the light chain is linked to the third cysteine (from the N-
terminus) of the heavy chain in IgG2 (and also IgG4), whereas in IgG1 it is linked 
to the fifth cysteine.  
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Due to their relevance as biotherapeutics, and with the raise of the so-
called biosimilars in the pharmaceutical market,[3, 6] high-throughput and 
extensive characterization of the sequence and structure of IgGs is needed.[2] 
Mass spectrometry (MS) plays a pivotal role in analysis of IgGs. MS-based 
methods have been developed and implemented across all stages of mAb 
production.[4] The basic workflow may include intact IgG mass measurement, 
IgG fragment (reduced light and heavy chains or papain-produced fragments) 
mass measurement (referred to as middle-up MS approach),[7] middle-down,[8, 
9] extended bottom-up[10] and bottom-up MS[2, 11] approaches. Although 
bottom-up approaches provide the most structural information today, they suffer 
a number of drawbacks such as artifact introduction and lengthy sample 
preparation.[12-14] Top-down mass spectrometry (TD MS)[15] refers to the gas-
phase dissociation of intact biomolecules and subsequent mass measurement of 
the fragmentation products. Applied to IgGs, TD MS is a convenient way to obtain 
primary structure information without the need of reducing the inter-chain 
disulfide bonds in solution. Furthermore, this approach generally allows access 
to sequence confirmation of terminal regions as well as variable domains. It also 
allows the identification and localization of major modifications and the 
characterization of major glycoforms.[16] It has the advantage of requiring a 
highly simplified sample preparation and therefore minimal artifact introduction 
induced by sample processing. Despite these advantages, TD MS is not yet 
routinely used for the characterization of mAbs, primarily due to the large 
number of highly charged products yielded by IgG fragmentation, which requires 
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high-resolution MS and the applications of techniques aimed at improving 
sensitivity, such as spectral summation (averaging).[17]  
Electron capture dissociation (ECD)[18, 19] and electron transfer 
dissociation (ETD)[20] of whole proteins usually generate larger sequence 
coverage than slow-heating activation methods (such as collision-induced 
dissociation, CID).[21] ECD and ETD MS/MS are also known as powerful 
methods for characterization of labile post-translational modifications, e.g., 
glycosylation.[22, 23] Fourier transform ion cyclotron resonance (FT-ICR) MS 
provides the highest resolution and can be hyphenated with ECD, making it the 
technique of choice for earlier TD MS experiments.[24-26] Notably, Mao et al. 
achieved 25% sequence coverage of a purified IgG1 using qFT-ICR MS and ECD 
when isolating a single charge state in a direct infusion ionization mode. They 
increased the sequence coverage to ~33% with a broadband tandem mass 
spectrometry (MS/MS), e.g., using all the IgG1 ions present in the charge state 
envelope as precursors for ECD.[27] However, the general use of FT-ICR MS 
instruments for IgG characterization is rare,[4] presumably due to their limited 
presence in biopharmaceutical laboratories owing to the tedious maintenance 
and operational costs, as well as oftentimes low efficiency of heavy precursor ion 
transfer and capture in the ICR cells for subsequent ECD reaction.  
With the advent of ETD efficiently performed in an external ion trap with 
product ion detection in a high-resolution mass analyzer, e.g., Orbitrap 
FTMS[28], FT-ICR MS,[29] or time-of-flight (TOF) MS,[30, 31] the performance of 
TD MS has improved. Particularly, TD MS of proteins on-line separated with 
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reversed phase liquid chromatography (LC) prior to electrospray ionization (ESI) 
became possible routinely.[32, 33] We have previously described the use of ETD 
with a high-resolution qTOF MS reporting the overall sequence coverage of 21% 
for mouse IgG1 and 15% for human IgG1 which provided structural information 
on variable domains of both the heavy and the light chain.[34] As a result of a 
more extensive investigation, we achieved 33% sequence coverage of a human 
IgG1 using ETD with a hybrid linear ion trap-Orbitrap FTMS (considering c-, z- 
and y-type product ions) equipped with a standard (moderate electric field, D30 
type) Orbitrap mass analyzer (Orbitrap Velos Pro). The results obtained with 
narrow (i.e., 100 m/z) and large (i.e., 600 m/z) isolation windows for precursor 
ions were combined to increase the final number of identified product ions.[17] 
In all the aforementioned TD MS studies, over one thousand (micro)scans (or 
transients in a time-domain domain, in the case of FTMS) were summed 
(averaged) to boost the sequence coverage.[17, 27, 34] Typically, several LC 
MS/MS runs were acquired followed by data summation (averaging) to provide 
the increased number of scans. The current state-of-the-art in TD MS, however, 
does not enable the full sequencing of the disulfide bond protected domains of 
light or heavy chain, neither it allows the direct localization of the glycosylation 
site in the CH2 domain of the heavy chain. This is due to the compact protein 
structure and its disulfide bond network (see Supporting Information, Figure 
S1), which is believed to constitute the major limitation in IgG TD MS 
characterization. Overall, the performance of all three approaches, using ETD on 
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a qTOF MS or on a linear trap-Orbitrap FTMS, as well as ECD on FT-ICR MS, 
provide comparable results.  
Here we investigated the potential of ETD implemented on a high-field 
compact Orbitrap FTMS, namely the Orbitrap Elite,[35] for faster top-down 
characterization of three therapeutic mAbs: adalimumab and trastuzumab (both 
of the IgG1 subclass), and the IgG2 panitumumab. The high-field Orbitrap mass 
analyzer is characterized by a higher frequency of ion oscillations along the 
central electrode compared to the prior generation of Orbitrap mass 
analyzers.[36, 37] Increased frequency of ion oscillations leads to the 
corresponding enhancement of the resolving power over a fixed acquisition time. 
Moreover, the implementation of a mixed absorption and magnitude mode FT of 
spectral representation (known as enhanced FT, or eFT algorithm)[38] allows a 
further gain (of up to two-fold) in acquisition rate at a constant resolution.[39] In 
addition to the advantages of the employed mass analyzer, we optimized 
precursor ion isolation and product ion transfer between the linear trap and the 
Orbitrap to increase the efficiency of ETD-based TD MS. Finally, IgG TD MS was 
performed under the optimized conditions with a two-stage ion activation 
method, a combination of ETD and higher-energy collision dissociation 
(HCD)[40] termed EThcD,[41] which has been recently applied to TD MS 
experiments, demonstrating sequence complementarity with ETD.[42, 43]  
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2. Materials and methods 
 
2.1 Chemicals. Water, acetonitrile (ACN), methanol (MeOH), formic acid (FA) 
and trifluoroethanol (TFE) were obtained in LC-MS purity grade. Water, ACN and 
MeOH were purchased from Fluka Analytical (Buchs, Switzerland). FA was 
obtained from Merck (Zug, Switzerland), and TFE from Acros Organics (Geel, 
Belgium).  
  
2.2 Sample preparation. Therapeutic monoclonal antibodies of the IgG1 class, 
namely adalimumab (Humira, Abbott Laboratories) and trastuzumab (Herceptin, 
Genentech), as well as the IgG2 panitumumab (Vectibix, Amgen) are the 
European Medicines Agency approved versions and formulations, available 
commercially to the general public. Prior to direct infusion analysis, all 
antibodies were buffer exchanged against a 150 mM ammonium acetate solution 
pH 6.7 using Micro-Spin desalting columns (Zeba 75 µL, Thermo Fisher 
Scientific, Zug, Switzerland).  
 
2.3 Sample delivery and ionization. The antibodies were injected into the 
mass spectrometer either by on-line coupled LC or by direct infusion in a positive 
ion mode of ESI. In the former case, we employed an UltiMate 3000 LC system 
(Thermo Fisher Scientific) equipped with a reversed phase C4 column (Hypersil 
Gold, 1x100 mm, 5 µm particle size, Thermo Fisher Scientific, Runcorn, UK), 
applying a gradient of ACN from 5 to 80% in 20 min, in presence of 0.1% FA, and 
10 
 
a flow rate of 100 µl/min generated by the loading pump. 1.5 µg of antibody (~10 
pmol), diluted in 20% ACN and 0.1% FA, were typically loaded in each injection, 
resulting in ~2 min elution of the IgG. The IonMax ion source (Thermo Fisher 
Scientific) was operated at 3.7 kV, with sheath gas set to 20 and auxiliary gas to 
10 arbitrary units. In the latter case, the antibody, buffer exchanged as described 
above, was diluted in 50% ACN and 0.1% FA to a final concentration of ~10 µM; 
6 µl of this IgG solution were loaded in a 20 µl loop connected to the injection 
valve of the LC system and infused through a silica capillary to the nanoESI 
source (Nanospray Flex ion source, Thermo Fisher Scientific) equipped with a 
metallic emitter to which a 2.4 kV voltage was applied. The composition of the 
solution used to push the IgG from the loop to the source was 39.9% water, 30% 
ACN, 20% MeOH, 10% TFE, and 0.1% FA. The flow rate generated by the nano-
pump of the LC system was 0.6 µl/min.  
 
2.4 Mass spectrometry. All experiments were performed on a hybrid dual linear 
ion trap high-field Orbitrap FT mass spectrometer (Orbitrap Elite, Thermo 
Scientific, Bremen, Germany) equipped with ETD and HCD. Similarly to our 
previous report,[17] the S-lens RF level was set to 70% and the temperature of 
heated transfer capillary was 350° C. Broadband mass spectra of intact IgGs and 
tandem mass spectra of the same molecules were recorded in separate 
experiments using ion detection in the Orbitrap FTMS (m/z 200-4000). All 
Orbitrap FTMS scans were recorded averaging 10 microscans to improve the 
SNR. Orbitrap FTMS was calibrated in the high mass range (m/z 2000-4000) 
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using ion at 2021.93954 m/z of commercial LTQ Velos ESI Positive Ion 
Calibration Solution (Thermo Fisher Scientific). Intact mass measurements of 
IgGs were performed at 15’000 resolution at 400 m/z with a target value of 
charges (automatic gain control, AGC) of 1 million. For ETD experiments, 
precursor ions were isolated between m/z 2400 and 2900 in the high pressure 
LTQ and subsequently subjected to ETD reaction. The AGC value for 
fluoranthene radical anions was set to 2 million charges, anion maximum 
injection time was set to 50 ms and ETD duration (i.e., ion-ion interaction time) 
was set either to 10 or 25 ms. Product ion detection in the Orbitrap mass analyzer 
was performed with 120’000 resolution (at 400 m/z, eFT enabled) and an AGC 
for precursor ions of 1 million charges.  
For both intact mass measurements and MS/MS, the gas (N2) “delta 
pressure” was of 0.1E-10 torr. The delta pressure corresponds to the difference 
in the pressure measured in the so-called ultra-high vacuum region (i.e., UHV 
region, or Orbitrap chamber) when nitrogen is injected into the HCD cell and 
when the gas is completely shut down. A delta value of 0.1E-10 torr likely 
corresponds to a pressure of ~1-2 mtorr of N2 in the HCD cell. Typically the delta 
pressure for bottom-up proteomics (i.e., smaller size ions) is ~0.35E-10 torr. 
Therefore, for TD MS the N2 gas pressure in the HCD cell is reduced compared to 
the bottom-up proteomics. To further improve ion transmission to the high-
resolution mass analyzer from the linear trap, ions ejected from the linear trap 
were first collisionally cooled in the HCD cell (a technique known as “HCD 
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trapping”), then transferred backward to the C-trap, and finally injected into the 
Orbitrap as previously described.[44]  
EThcD experiments were performed as follows. After ETD with 10 ms 
duration, all ETD products, including both charge-reduced species and product 
ions (precursors are generally completely consumed in ETD under the applied 
conditions), were transferred from the linear trap to the HCD cell. Here an axial 
potential was set to 25 or 40 V, so that instead of ion capture and relaxation a 
second ion activation event could occur. Finally, ions were transferred back to 
the C-trap and further into the Orbitrap for detection.  
 
2.5 FTMS data processing and analysis. The data processing routine for 
obtaining tandem mass spectra with an improved SNR was performed as 
previously described.[17] Briefly, in both LC-MS/MS and direct infusion MS/MS 
experiments, Orbitrap FTMS time-domain transients were recorded in MIDAS 
.dat format[45] and underwent summation (averaging) before being processed for 
time-to-frequency conversion. In this way it was possible to sum 384 ms 
transients derived from separate LC runs or distinct direct infusion experiments. 
Enhanced Fourier transform, eFT, or a standard magnitude mode Fourier 
transform, mFT, was then applied to process transients and yield frequency-
domain spectra (internal processing at Thermo Fisher Scientific).[38] The thus 
obtained frequency spectra were then converted into .RAW mass spectra (internal 
processing at Thermo Fisher Scientific) for further viewing and processing with 
XCalibur software (Thermo Fisher Scientific), as well as data analysis (vide infra). 
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Final ETD mass spectra were derived from summed transients recorded for 10 
and 25 ms ETD duration experiments. For an in-depth evaluation of the effect of 
ETD duration on IgG fragmentation, 10 and 25 ms ETD datasets were also 
analyzed separately. The resolution gain of eFT versus mFT is known to be two-
fold.[38] However, to demonstrate the practically useful and presumably 
sufficient resolution requirement for analysis of top-down ETD mass spectra of 
IgGs, only the mFT-processed data are reported here. Results obtained with eFT 
signal processing were found to be comparable to the mFT processing in terms 
of protein sequence coverage (data not shown). 
Previously, the combination of Xtract deconvolution software and ProSight 
PC 3.0 product ion assignment software (both from Thermo Fisher Scientific) was 
successfully employed for IgG TD MS data analysis.[30] Here, we extended this 
approach by adding a workflow combining the MS-Deconv deconvolution 
algorithm and MS-Align+ product ion assignment software (both developed at 
University of California San Diego, CA, USA).[46] A comparison between the 
results produced by MS-Deconv/MS-Align+ and by Xtract/ProSight PC is 
presented in Figure S2, Supporting Information. Both the data analysis packages 
led to comparable results. In greater detail, the MS-Deconv/MS-Align+ analyses 
were realized according to the following steps: (i) ReAdW software was used to 
convert .RAW files of ETD mass spectra into centroided mzXML files; (ii) a 
customized version of MS Deconv was used to deconvolute the mzXML files using 
a SNR cutoff of 3. The custom version of MS-Deconv was written to process the 
data sets containing MS/MS information only, whereas the standard version of 
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MS-Deconv requires both MS and the directly corresponding to it MS/MS data 
sets; (iii) MS-Align+ was used for product ion identification, considering c- and 
z·- type ions for ETD experiments and c-, z·-, b- and y-type ions for EThcD data. 
Cysteine residues were considered as not modified and all the mass tolerances 
were set to 20 ppm. Manual validation was performed for cleavage sites identified 
from product ions present only in a single charge state. The graphical 
fragmentation maps reported herein were realized using either ProSightPC or 
ProSight Lite software.[47] 
 
2.6 Product ion abundance analysis. Abundances of identified product ions 
were derived from MS-Align+ analysis. For each cleavage site, all the related 
product ions were considered and grouped. Final abundances were obtained by 
dividing the abundance values reported for each product ion over the ion charge 
state, and summing all the resulting charge-normalized abundance values of 
product ions generated from a single cleavage site. For plotting together product 
ion abundance (PIA) analysis results of different sets of data, the abundances 
were expressed as relative percentages of the most abundant product ion cluster 
(i.e., the group of all the z-type ions, with different charge state, derived from a 
single cleavage site) in each data set.  
 
3. Results and discussion 
3.1 Optimization of ETD MS/MS of IgG. To maximize ETD efficiency, we sought 
to first optimize precursor cation selection and product ion transfer. In the 
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former work based on an Orbitrap Velos Pro mass spectrometer we isolated 
adalimumab precursor ions around m/z 2750 (isolation window width: 100 m/z, 
precursor ions from 53+ to 55+) or 2900 (isolation window width: 600 m/z, 
precursor ions from 47+ to 57+). Considering the charge state envelope obtained 
with the current LC-MS setting on the Orbitrap Elite for intact adalimumab, we 
centered the isolation window at m/z 2700, with a width of 600 m/z, thus 
including precursors from 50+ to 61+ (Figure S3, Supporting Information). 
Higher charge state precursor ions are supposed to increase the fragmentation 
efficiency in ETD and facilitate the separation of obtained product ions bound by 
non-covalent bonds. Furthermore, cleavage preferences within protein structure 
shift as a function of charge location. In regard to product ion transfer, we 
applied a combination of reduction of the gas pressure in the HCD cell and the 
“HCD trapping” technique, vide supra. The gas pressure reduction improves SNR 
of large product ions by improving their transmission from LTQ into the HCD 
cell and further within the Orbitrap analyzer. Trapping of ions in the HCD cell 
(and not directly and only in the C-trap) allows the improved transmission also 
of lighter ions, presumably counterbalancing the reduced damping effect in the 
C-trap resulting from the lower gas pressure (Figure S4, Supporting 
Information).  
Overall, the implementation of these settings allowed for SNR increases in 
the MS/MS mode for high m/z ions, which resulted in a reduction of the number 
of transients that needed to be summed to obtain high-quality mass spectra in 
comparison to our previous work, vide infra. Each ETD mass spectrum derived 
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from a combination of transients was obtained applying two different ion-ion 
interaction times, 10 and 25 ms, Figure 1. These two ETD durations were chosen 
to allow a direct comparison with our previous work, where we combined ETD 
MS/MS data resulting from shorter and longer ion-ion interaction times, pre-
selected for fragmentation of intact denatured IgG precursor ions. Increasing 
ETD duration enhanced the formation of product ions with a reduced charge 
state, likely because of the occurrence of multiple electron transfer and 
consequent charge reduction events. Nevertheless, the separate analysis of mass 
spectra obtained with 10 or 25 ms ETD duration revealed that most of the 
identified cleavage sites are shared between the two experiments (see product 
ion abundance analysis results below), suggesting that ETD is primarily limited 
by the retention of a compact conformation of the IgG in the gas phase. Summing 
transients from these two experimental sets, though, increased the confidence 
in the assignment of cleavage sites, as product ions obtained by the same 
backbone cleavage are identified in multiple charge states. 
 
3.2 ETD and EThcD MS/MS of intact human IgG1. The analysis of product 
ions obtained by ETD MS/MS was performed for two IgG1 mAbs, adalimumab 
and trastuzumab. Their sequences are 92% homologous, the differences being 
almost entirely localized to the complementarity determining regions (CDRs) 
involved in the antigen binding. Figure 2 A displays the ETD fragmentation map 
of adalimumab, with the typical fragmentation pattern expected for this IgG 
isotype. Extensive fragmentation is achieved on the heavy chain for the loop 
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interconnecting VH and CH1, the loop between CH2 and CH3 and part of the CH3 
domain; on the light chain, the characterized region is represented by the loop 
between VL and CL. For both chains, therefore, the sequenced areas are mainly 
disulfide bond-free loops exposed to the solvent. The results of ETD MS/MS 
application to trastuzumab are nearly identical to those for adalimumab (Figure 
S5, Supporting Information). For both the IgGs only the CDR3 domains of light 
and heavy chains are fully sequenced, and only a few product ions positioned on 
CDR2 of heavy and light chain have been assigned for trastuzumab (which shows 
slightly higher sequence coverage). As summarized in Table 1, 310 ETD MS/MS 
scans (which corresponds to 3100 microscans or transients) were summed to 
result in 23.8% and 26.5% sequence coverage for adalimumab and trastuzumab, 
respectively. Notably, from the comparison of these results and the previously 
reported ones it is apparent how, although the total sequence coverage (i.e., sum 
of cleavages in light and heavy chains) is similar, the distribution of identified 
cleavage sites between the two chains is changed, with the heavy chain being 
more sequenced in the present report than in the previous one. For trastuzumab 
we reached 29% sequence coverage which represents the highest value obtained 
so far for the heavy chain of an intact IgG1 by ETD TD MS. On the other hand, 
the light chain has been less sequenced with the new settings and data analysis 
routine than in the past, but also for the drastically reduced number of scans 
considered. Manual inspection of MS/MS spectra reveals that the missing 
product ions are mainly those arising from cleavage sites located at the two 
termini of the light chain: these are light, lowly charged ions that presumably 
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were not favorably transmitted with the newly employed settings (Figure S4, 
Supporting Information). The fully sequenced region in the light chain, 
corresponding to the loop between VL and CL, as mentioned above, remained the 
same between the two studies, and it is equal between adalimumab and 
trastuzumab (both of which often show complementary c- and z-type ions for the 
same cleavage site). Cleavages outside this area do not follow any clear pattern 
and seem randomly distributed. 
To improve the sequence coverage of the IgG1 and, specifically, of the light 
chain, we applied EThcD on adalimumab. We summed transients obtained with 
EThcD (i.e., both product ions and charge-reduced species) performed at both 
25 and 40 V. As shown in Figure 2B, EThcD produced fragmentation mainly in 
the same areas previously covered by ETD, but also induced new cleavages at 
the N-terminus of both light and heavy chain, and provided b- and y-type ions 
from the N-terminal side of proline that could not be previously identified from 
ETD data. The sequence coverage for the heavy chain of adalimumab is lower 
than for ETD, but it passed from ~19% to ~28% for the light chain, as reported 
in Table 1. Overall, the combination of 310 ETD scans and 260 EThcD scans, 
for a total of 570 scans, produced 30.5% sequence coverage, which is the same 
result obtained by averaging 1360 scans in our previous work based on the 
Orbitrap Velos Pro. In addition to the reduced number of scans, a two-fold scan 
speed improvement due to the implementation of the high-field Orbitrap mass 
analyzer (higher frequency of ion axial oscillations) decreased the required 
experimental time for mFT signal processing. Further two-fold improvement can 
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be achieved by the application of eFT signal processing. For instance, at 120’000 
resolution (at 400 m/z, eFT signal processing) and under LC-MS/MS conditions, 
120 transients (microscans) could be recorded per minute of IgG elution on the 
Orbitrap Elite FTMS versus the previous 40 transients (microscans) on the 
Orbitrap Velos Pro (mFT signal processing, 100’000 resolution at 400 m/z). The 
ETD MS/MS experimental sequence, including cation accumulation, anion 
injection and subsequent cation/anion interaction largely contributes to the 
duty cycle, partially counterbalancing the time gain in FTMS data acquisition 
due to combination of high-field Orbitrap and eFT.  
Finally, from the comparison of the ETD TD MS results obtained with 
different ion transfer parameters (especially the pressure conditions in the HCD 
cell), those reported here and in the previous work, it seems beneficial to acquire 
ETD TD MS data with both conditions and pool the data together.  Indeed, results 
reported in Figure S6 (Supporting Information) show that the sequence coverage 
for ETD MS/MS of adalimumab with only c and z-ions is increased to 41.3% and 
34.7% for light and heavy chain, respectively, with a total sequence coverage of 
36.8%. 
 
3.3 Product ion abundance analysis of ETD MS/MS of IgGs1. A PIA analysis 
was conducted on ETD MS/MS data for the C-terminal portions of the almost 
completely sequenced heavy chains of the investigated IgGs1. Figure 3 shows a 
comparison between the relative abundances of z-ions from 10 ms ETD of 
adalimumab, as well as 10 ms and 25 ms ETD of trastuzumab. Note that the 
20 
 
two IgGs share identical sequence in the analyzed area. For all three data sets, 
the average abundance of product ions generated by the disulfide-free loop 
connecting CH2 and CH3 is ~40% of the maximum, and global maxima are all 
located there. Conversely, ions derived from the disulfide-protected area of CH3, 
as well as those from the disulfide-free C-terminal end (which is, structurally 
speaking, a part of the CH3 domain), generally have an abundance lower than 
10% of the corresponding maximum. Furthermore, the global maxima for the 
two 10 ms ETD data sets are both located at the cleavage site between K105 and 
G106 (which results in z106 ions). Other local maxima correspond to the formation 
of z96, z93, and z86 ions. The 25 ms data set shows a similar trend, with z106 still 
abundant but surpassed by z93, z91, and z86. Therefore, the ETD results are 
conditioned by the secondary and tertiary structures of the gaseous protein ions. 
Moreover, similarly to ECD MS/MS,[48] the ETD radical process seems to be 
affected by the electron transfer site, as the presence of basic residues at one 
side of the cleavage maxima would suggest. Finally, the shift in maxima 
occurring when passing from 10 to 25 ms ETD might be explained by the 
increased probability of secondary electron transfer events when the ETD 
duration is prolonged. The occurrence of secondary electron transfer and 
consequent charge neutralization events might be confirmed by the reduced 
average charge state of the product ions identified for 25 ms ETD in comparison 
to 10 ms ETD experiments (Table S1, Supporting Information). The data suggest 
that these events are most prominent at the flexible loop and with a CH3 domain 
in a compact conformation. Therefore, despite the second fragmentation event, 
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the abundance of product ions originated within the sequence of the CH3 domain 
is not higher than for the 10 ms experiments. Instead, we observe the shift 
between z106 and z86 as maxima in the disulfide-free region. Visually, this is 
represented in Figure 4 through a color-coded map based on crystal structure 
of trastuzumab (image elaborated with The PyMol Molecular Graphics System, 
version 1.3, Schrodinger, LLC). The passage from 10 ms to 25 ms ETD duration 
induces the translation of highly frequent cleavage sites (represented in red) 
towards the C-terminus, but still in solvent accessible positions. On the contrary, 
the compact “immunoglobulin-like domain” corresponding to CH3, which 
resembles the structure of a beta barrel, and contains an intra-molecular 
disulfide bridge, remains poorly sequenced (and thus represented in black-blue). 
These results reinforce the hypothesis that IgGs retain a relatively compact high-
order structure in the gas phase, even under denaturing ionization conditions. 
 
3.4 ETD MS/MS of intact human IgG2. ETD MS/MS was performed on 
panitumumab, an IgG2, to provide a confirmation to our hypothesis that 
limitations in sequence coverage achieved for IgGs1 are mainly attributable to 
gas-phase retention of a structured, compact conformation by the protein. As 
displayed in Figure 5, identified product ions for this IgG are localized in the 
areas sequenced in the experiments involving adalimumab and trastuzumab, 
e.g., the solvent accessible loops interconnecting consecutive disulfide-protected 
domains and the CH3 domain. In-depth analysis reveals that the C-terminal 
portion of the heavy chain is highly sequenced, with 83 assigned z-type ions 
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versus 82 z-ions identified for trastuzumab, which has overall the highest 
sequence coverage for its heavy chain (Table 1). Nevertheless, given that, in 
accordance to what is observed for IgGs1, the hinge region is not sequenced also 
in the case of panitumumab, differences between the two IgG isotypes are 
present in the loop interconnecting VH and CH1. In the case of IgGs1, this loop 
was fully sequenced, whereas for panitumumab only partial sequencing was 
achieved. This can be explained by the presence in the loop of the IgG2 of Cys133, 
involved in an inter-molecular disulfide bridge connecting the heavy with the 
light chain. Notably, most of the identified c-type product ions are located to the 
N-terminus of C133. Further studies are needed to determine whether ETD 
cleavages were primarily impeded in the portion of the loop at the C-terminal 
side of C133 or, conversely, cleavages occurred but primarily produced product 
ions with portions of the light chain still present and were therefore not 
identifiable by the present version of the data analysis approach. Finally, 
panitumumab’s light chain has been sequenced in its central area (i.e., disulfide-
free loop between VL and CL), similarly to IgGs1, but its incomplete sequencing 
and, importantly, the limited number of identified z-ions (nine, corresponding to 
only ~50-30% of those assigned in the other experiments), could indicate that 
the inter-molecular disulfide bridge with the heavy chain is less efficiently 
cleaved in IgG2 than in IgG1.  
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4. Concluding remarks 
Developments in Orbitrap FTMS technology mark a substantial improvement in 
top-down MS performance. Experimentally, around three-fold faster acquisition 
of IgG ETD data under optimized conditions in the Orbitrap Elite (high-field 
compact Orbitrap analyzer) combined with a more than two-fold reduction in the 
number of transients to be summed as required for a comprehensive top-down 
analysis of IgGs resulted in about six-fold reduction of acquisition time in the 
present study relative to the analysis with the Orbitrap Velos Pro. For the latter, 
a standard trap with mFT yielded resolution of 100’000 at 400 m/z. Here, 
resolution of 60’000 (at 400 m/z) was provided with mFT signal processing and 
120’000 (at 400 m/z) when eFT algorithm was employed. The (moderate) level of 
product ion spectral complexity generated in this top-down experiment, perhaps 
due to a symmetric subunit structure of IgGs, demonstrated similar performance 
in sequence coverage for mFT and eFT-generated mass spectra. The following 
factors contributed to the reduction of number of scans needed for high quality 
TD MS analysis: (i) selection of higher charged precursors, (ii) optimization of 
transfer of large ETD product ions from the linear trap to the Orbitrap by 
lowering the HCD cell gas pressure, (iii) combination of experiments conducted 
with different ion-ion reaction times, and (iv) use of EThcD with two different 
collisional energy values. Nevertheless, the previously determined limit in 
sequence coverage, ~30%, could not be overcome. The primary cause for the 
limited sequence coverage is the gas-phase retention of highly structured areas 
in the IgG, mainly in correspondence of the immunoglobulin-like domains.  
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To facilitate user access to the described technology, algorithms and 
methods for spectral summation across different experiments or/and for 
transient acquisition and subsequent signal processing (absorption mode FT) of 
summed transients where needed by spectral complexity have been made 
commercially available (Spectroswiss, Lausanne, Switzerland). Further 
extending the sequence coverage in TD MS of IgGs may be provided by an 
improved ETD reaction cell,[49] chemical ionization source for front-end ETD on 
Orbitrap FTMS,[50] and the use of ion activation methods alternative to ETD, 
e.g., ultraviolet photodissociation.[51] Furthermore, improved sequence coverage 
is achievable by combining ETD experimental data acquired with high HCD gas 
pressure (i.e., maximizing light product ion transmission), and low gas pressure 
(i.e., maximizing heavy product ion transmission), as it results from the 
combination of present data with those acquired in standard operational 
conditions with the Orbitrap Velos Pro. Finally, the probable presence of internal 
products and product ions retaining parts of both light and heavy chains bonded 
by inter-molecular disulfide bridges will require developments in the data 
analysis tailoring this specific class of proteins. 
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Figure captions 
 
Figure 1. Top-down ETD Orbitrap FTMS of IgG1 (adalimumab) with ion-ion 
interaction time of 10 and 25 ms. (A) Combined mass spectrum including 
transients from both 10 and 25 ms measurements, with product ion population 
arising from the former experiment highlighted in blue, and from the latter 
indicated in red. (B) and (C) Expanded views of the two product ion populations, 
with assigned product ions derived from the heavy chain. Note the difference in 
the average charge state of the product ions of the two populations. 
 
Figure 2. Fragmentation map of adalimumab by top-down Orbitrap FTMS. (A) 
ETD MS/MS. (B) EThcD MS/MS. The heavy chain information is on top, the light 
chain information is at the bottom. 
 
Figure 3. Product ion abundance analysis of ETD top-down MS of adalimumab 
with 10 ms ETD duration and trastuzumab with 10 and 25 ms duration. In the 
case of trastuzumab, the color-coded histogram demonstrates the improvement 
in sequence coverage obtained through the combination of 10 ms (magenta) and 
25 ms (cyan) ETD MS/MS data. Whereas medium and large product ions (e.g., 
z117 and z63) are generally produced using 10 ms duration, smaller ions such as 
z16, z17 and z18 are detected only in the case of a longer ETD duration, presumably 
as the result of secondary fragmentation (i.e., re-fragmentation of larger product 
ions). 
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Figure 4. Color-coded representation of ETD PIA results for the C-terminus of 
the heavy chain of trastuzumab. (A) 10 ms ETD. (B) 25 ms ETD. The displayed 
image is based on X-ray crystallography data (PDB entry: 3D6G). 
 
Figure 5. Fragmentation map of panitumumab (IgG2) obtained with top-down 
ETD Orbitrap FTMS. 
 
Table 1. Sequence coverage obtained for different IgGs1 and IgG2 by top-down 
ETD Orbitrap FTMS. Indicated scans consist of 10 microscans each. Note, only 
c- and z-type ions were considered for ETD MS (for both “high-field” and 
“standard” Orbitrap data), whereas also b- and y-type ions were included in 
EThcD MS analysis. 
 
Table 1. 
 
 
 
 
 
 
Number of 
scans
N‐terminal 
product ions
C‐terminal 
product ions
Unique 
cleavage sites
Sequence 
coverage
N‐terminal 
product ions
C‐terminal 
product ions
Unique 
cleavage sites
Sequence 
coverage
high‐field Orbitrap
Adalimumab ETD 310 34 19 41 19.2% 39 78 117 26.0% 23.8%
Adalimumab EThcD 260 45 29 59 27.7% 22 58 80 17.8% 21.0%
Adalimumab combined 570 50 32 67 31.5% 53 82 135 30.0% 30.5%
Trastuzumab ETD 310 37 19 45 21.1% 55 75 130 29.0% 26.5%
Panitumumab ETD 300 34 9 34 15.9% 23 83 106 23.9% 21.3%
standard Orbitrap
Adalimumab combined 1360 54 59 84 39.4% 60 79 119 26.4% 30.6%
Light chain Heavy chain Total sequence 
coverage
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